Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $33.57 billion. The enterprise value is $39.44 billion.
| Market Cap | 33.57B |
| Enterprise Value | 39.44B |
Important Dates
The last earnings date was Wednesday, April 24, 2024, before market open.
| Earnings Date | Apr 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 145.60 million shares outstanding. The number of shares has increased by 0.48% in one year.
| Shares Outstanding | 145.60M |
| Shares Change (YoY) | +0.48% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 93.29% |
| Float | 145.09M |
Valuation Ratios
The trailing PE ratio is 28.79 and the forward PE ratio is 14.39. Biogen's PEG ratio is 6.24.
| PE Ratio | 28.79 |
| Forward PE | 14.39 |
| PS Ratio | 3.47 |
| Forward PS | 3.47 |
| PB Ratio | 2.21 |
| P/FCF Ratio | 26.14 |
| PEG Ratio | 6.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.29, with an EV/FCF ratio of 30.71.
| EV / Earnings | 33.81 |
| EV / Sales | 4.08 |
| EV / EBITDA | 21.29 |
| EV / EBIT | 29.82 |
| EV / FCF | 30.71 |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.46.
| Current Ratio | 2.10 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 3.75 |
| Debt / FCF | 5.41 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.90% and return on invested capital (ROIC) is 5.27%.
| Return on Equity (ROE) | 7.90% |
| Return on Assets (ROA) | 4.40% |
| Return on Capital (ROIC) | 5.27% |
| Revenue Per Employee | $1.28M |
| Profits Per Employee | $154,108 |
| Employee Count | 7,570 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Biogen has paid $156.00 million in taxes.
| Income Tax | 156.00M |
| Effective Tax Rate | 11.79% |
Stock Price Statistics
The stock price has decreased by -24.71% in the last 52 weeks. The beta is -0.01, so Biogen's price volatility has been lower than the market average.
| Beta (1Y) | -0.01 |
| 52-Week Price Change | -24.71% |
| 50-Day Moving Average | 213.09 |
| 200-Day Moving Average | 239.51 |
| Relative Strength Index (RSI) | 66.22 |
| Average Volume (30 Days) | 1,245,074 |
Short Selling Information
The latest short interest is 3.15 million, so 2.16% of the outstanding shares have been sold short.
| Short Interest | 3.15M |
| Short Previous Month | 3.26M |
| Short % of Shares Out | 2.16% |
| Short % of Float | 2.17% |
| Short Ratio (days to cover) | 2.40 |
Income Statement
In the last 12 months, Biogen had revenue of $9.66 billion and earned $1.17 billion in profits. Earnings per share was $8.01.
| Revenue | 9.66B |
| Gross Profit | 7.25B |
| Operating Income | 1.32B |
| Pretax Income | 1.32B |
| Net Income | 1.17B |
| EBITDA | 1.85B |
| EBIT | 1.32B |
| Earnings Per Share (EPS) | $8.01 |
Balance Sheet
The company has $1.07 billion in cash and $6.95 billion in debt, giving a net cash position of -$5.87 billion or -$40.33 per share.
| Cash & Cash Equivalents | 1.07B |
| Total Debt | 6.95B |
| Net Cash | -5.87B |
| Net Cash Per Share | -$40.33 |
| Equity / Book Value | 15.21B |
| Book Value Per Share | 104.49 |
| Working Capital | 3.53B |
Cash Flow
In the last 12 months, operating cash flow was $1.65 billion and capital expenditures -$360.70 million, giving a free cash flow of $1.28 billion.
| Operating Cash Flow | 1.65B |
| Capital Expenditures | -360.70M |
| Free Cash Flow | 1.28B |
| FCF Per Share | $8.85 |
Margins
Gross margin is 75.03%, with operating and profit margins of 13.69% and 12.07%.
| Gross Margin | 75.03% |
| Operating Margin | 13.69% |
| Pretax Margin | 13.69% |
| Profit Margin | 12.07% |
| EBITDA Margin | 19.17% |
| EBIT Margin | 13.69% |
| FCF Margin | 13.29% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.48% |
| Shareholder Yield | -0.48% |
| Earnings Yield | 3.48% |
| FCF Yield | 3.83% |
Analyst Forecast
The average price target for Biogen is $288.83, which is 25.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $288.83 |
| Price Target Difference | 25.27% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 2.07% |
| EPS Growth Forecast (5Y) | 23.53% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.41 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.41 |
| Piotroski F-Score | 4 |